Annexon, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Annexon, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing novel therapies targeting neuroinflammatory and autoimmune diseases via complement pathway inhibition. Founded in 2017 and headquartered in Brisbane, California, Annexon focuses on treating classical complement-mediated diseases affecting the brain, body, and eye. Its core product pipeline includes ANX005, an investigational monoclonal antibody in a pivotal Phase III trial for Guillain-Barré Syndrome; ANX007, an antigen-binding fragment in Phase III trials for geographic atrophy in dry age-related macular degeneration; ANX1502, an oral small molecule for autoimmune indications; and ANX009, a C1q-blocking fragment designed for subcutaneous delivery. The company develops and anticipates commercializing therapies primarily in the autoimmune, neurodegeneration, and ophthalmology sectors targeting rare, high-unmet medical needs. Its product candidates undergo late-stage clinical development with dosing modalities including intravenous, intravitreal, and oral administration. Annexon operates primarily in the United States but aims for regulatory approvals and commercialization potential in both the U.S. and Europe. Recent major developments include the initiation and ongoing enrollment of pivotal Phase III trials for ANX007 in geographic atrophy, planning head-to-head trials against market competitors such as SYFOVRE® (pegcetacoplan), and preparing for Biologics License Application filings for ANX005 based on clinical data anticipated by late 2024. In 2025, the company launched a $75 million public offering to support continued advancement of its neuroinflammatory treatment pipeline and expanded strategic investor interest through Nuveen LLC’s acquisition of a minority stake aligned with its high-yield resilience investment strategy. Annexon also plans to present focused R&D updates highlighting the therapeutic potential of its portfolio. Annexon sustains its business through strategic clinical program progression and investment support aimed at delivering transformative therapies for debilitating complement-driven diseases. This description summarizes Annexon's role as a clinical-stage biotechnology firm with a detailed focus on complement inhibition platforms and its recent financial and strategic developments in the last 1-2 years.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon to Participate in Upcoming June Investor Conferences
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
Annexon (NASDAQ:ANNX) Shares Down 6.1% – Should You Sell?
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)